Durvalumab in NSCLC: latest evidence and clinical potential

Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease setting...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Unceta, Nerea, Burgueño, Isabel, Jiménez, Elizabeth, Paz-Ares, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187424/
https://www.ncbi.nlm.nih.gov/pubmed/30344651
http://dx.doi.org/10.1177/1758835918804151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6187424/
https://www.ncbi.nlm.nih.gov/pubmed/30344651
http://dx.doi.org/10.1177/1758835918804151

Ejemplares similares